As artificial intelligence (AI) transforms how life sciences organizations access and analyze real-world data (RWD), one challenge looms large: ensuring that these powerful tools are used appropriately.
RWD can illuminate patient outcomes, accelerate research, and guide better decision-making—but only when it’s handled ethically, transparently, and within the boundaries of contractual and regulatory use. Here are some ways to avoid the misuse of RWD with AI.
The Stakes of Responsible RWD Use
Historically, RWD analysis was controlled by trained data specialists who knew how to query data correctly and interpret it responsibly. Today, as AI makes RWD more accessible to a broader range of users that manual gatekeeping is fading. The result? Faster insights—but also a greater risk of improper use.
Pharma teams want fast, self-service access to insights, but they also need assurance that the AI tools they’re using understand both the technical and ethical nuances of the healthcare landscape. The key is using AI that’s purpose-built for life sciences and built by companies who have earned industry trust and validation as secure and compliant, with scientific tools already addressing and safeguarding for ethical and compliant RWD usage.
Embedding Guardrails into AI Tools
One effective strategy for reducing risk is building guardrails directly into the AI platform. For example, templates that are user-specific and approved by data analytics/scientist groups allow for flexibility, but also mitigate misinterpretation of the results. These templates provide consistency, repeatability and compliance across an organization, ensuring that multiple people asking similar questions of the tool should get the same or similar answers.
This approach to setting up the AI tool enables controls to be handled by the analytic/scientific groups within the organizations. As changes need to be made, they can be managed and locked down by these central teams. This provides both ownership and control for the teams responsible for monitoring RWD use.
Having those templates set up ensures that you can get to a result quickly, and all the Q&A happens in a templated environment. It saves time—and ensures that the data is being used the right way.
Guardrails should also be flexible enough to accommodate users of varying expertise. Less experienced users might rely on simple, structured prompts, while advanced analysts need the freedom to run deeper, more complex queries. The right balance allows both groups to operate efficiently without risking misuse.
Transparency and Traceability: Seeing How the “Sauce Is Made”
A common concern with AI systems is the so called “black box” issue, which means that users see the outputs but not the process. In pharma, where decisions are often peer-reviewed or audited, companies need visibility into how AI-generated results were produced: which datasets were used, which measures were applied, and over what timeframe.
Transparent AI tools enable teams to “show their work,” building confidence in both internal and external stakeholders. Traceability also plays a critical role in maintaining compliance. Role-based access controls and clear data lineage tracking ensure that every interaction with the data can be verified—reducing the risk of errors, misuse, or compliance violations.
Context Awareness: The Missing Ingredient
Even the most transparent AI systems can fail if they lack context. Without a deep understanding of how healthcare data works—how diagnoses are coded, how treatment pathways are defined—AI outputs can be misleading.
That means AI assistants built for pharma need more than general AI capabilities—they need to be grounded in the specific rules, ethics, and logic of the life sciences industry. They should support users in interpreting data correctly, not just generate answers quickly.
Building AI That’s Fit for Purpose
Not all AI tools are created equal. There’s an important distinction between an AI model, which learns and evolves autonomously, and an AI assistant, which is programmed with controlled logic and templates. For pharma applications, the latter often makes more sense, as it provides speed and efficiency without sacrificing oversight.
Companies also need to ensure that AI advances happen in a controlled yet flexible environment. Any change or advance in the tool should be anchored in the templates and parameters built for the use cases they support.
AI is unlocking enormous potential in real-world data, giving pharma teams faster and broader access to insights than ever before. But with that power comes responsibility. By embedding guardrails, ensuring transparency, and prioritizing contextual awareness, life sciences organizations can confidently harness AI’s power—without crossing the ethical or regulatory lines that protect patients and preserve trust.
Responsible AI isn’t just about compliance; it’s about credibility. The companies that get it right will not only avoid risk but also gain a strategic advantage—turning RWD into a truly reliable, scalable asset for discovery, development, and better patient outcomes.
This article was originally published in HealthEconomics.
For an introduction to Panalgo’s transparent, fit-for-purpose GenAI tool, visit our sister company’s site for Ella AI.
